首页 | 本学科首页   官方微博 | 高级检索  
     


CCN2: a bona fide target for anti-fibrotic drug intervention
Authors:Andrew Leask
Affiliation:Departments of Dentistry and Physiology and Pharmacology, University of Western Ontario, London, ON Canada N6A 5C1
Abstract:CCN2 (formerly known as connective tissue growth factor) was identified by several different laboratories approximately 20 years ago. Almost since its identification as a factor induced in normal fibroblasts by transforming growth factor β and overexpressed in fibrotic disease, CCN2 has been hypothesized to be not only a marker but also a central mediator of fibrosis in vivo. Finally, in vivo data are emerging to validate this key hypothesis. For example, a neutralizing anti-CCN2 antibody was found to attenuate fibrogenesis in three separate animal models (Wang et al. in Fibrogenesis Tissue Repair 4:1–4, 2011). This commentary addresses recent data indicating that CCN2 appears to represent a key central mediator of fibrosis and a good target for anti-fibrotic drug intervention.
Keywords:Ctgf   ccn2   Fibrosis   Bleomycin   UUO   Conditional knockout
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号